ScinoPharm, Foresee to form JV to develop oncological peptide drugs
The JV will formulate Leuprolide in a proprietary controlled-release drug delivery platform technology, developed by Foresee. Under the JV, ScinoPharm will act as the exclusive provider of Leuprolide